SOUTH SAN FRANCISCO, Calif., April 9, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences, Inc., (Nasdaq:HNAB), a biopharmaceutical company focused on developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care, today announced that its audited financial statements for the fiscal year ended December 31, 2008, included in the Company's Annual Report on Form 10-K, filed on March 31, 2009, contained a going concern qualification from its independent registered accounting firm, BDO Seidman, LLP.
